The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis
Open accessAbstract
The human oncoprotein MDM2 (hMDM2) overexpresses in various human tumors. If amplified, the mdm2 gene can enhance the tumorigenic potential of murine cells. Here, we present evidence to show that the full-length human or mouse MDM2 expressed from their respective cDNA can inhibit the G0/G1-S phase transition of NIH 3T3 and normal human diploid cells. The protein harbors more than one cell-cycle-inhibitory domain that does not overlap with the p53-interaction domain. Deletion mutants of hMDM2 that lack the cell-cycle-inhibitory domains can be stably expressed in NIH 3T3 cells, enhancing their tumorigenic potential. The tumorigenic domain of hMDM2 overlaps with the p53-interaction domain. Some tumor-derived cells, such as Saos-2, H1299 or U-2OS, are relatively insensitive to the growth-inhibitory effects of hMDM2. These observations suggest that hMDM2 overexpression in response to oncogenic stimuli would induce growth arrest in normal cells. Elimination or inactivation of the hMDM2-induced G0/G1 arrest may contribute to one of the steps of tumorigenesis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Normal cells tolerate small increases in Mdm2 levels.
“Small increases in Mdm2 levels in normal cells are tolerated”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Brown, et al., 1998
Higher Mdm2 levels are incompatible with life in vivo and in vitro, except in some cases when p53 is also inactivated.
“higher levels are incompatible with life in vivo and in vitro, except in some cases when p53 is also inactivated”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Brown, et al., 1998
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,673 · see citing works
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · cited 1× · see citing works
“A recent report (Serrano et al., 1997) has demonstrated that overexpression of oncogenic ras can induce G1 arrest of primary human and rodent cells.”
BackgroundCurrent Protocols in Immunology
(2018) · Current Protocols in Immunology · doi:10.1002/(issn)1934-368x · Cited by 3,574 · see citing works
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works
Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells
Gorman, C. M., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044-1051.1982 · Cited by 3,106 · see citing works
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814 · see citing works
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works
Molecular themes in oncogenesis
Bishop, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90636-d · Cited by 1,619 · see citing works
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 3× · see citing works
“The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis”
Backgroundmdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 3× · see citing works
“The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis”
BackgroundMonoclonal antibodies specific for simian virus 40 tumor antigens
Harlow, E., Crawford, L. V., Pim, D. C., & Williamson, N. M. (1981) · Journal of Virology · doi:10.1128/jvi.39.3.861-869.1981 · Cited by 1,038 · see citing works
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works
p53 Functions as a Cell Cycle Control Protein in Osteosarcomas
Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M. C., Bressac, B., Öztürk, M., Baker, S. J., Vogelstein, B., et al. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772 · Cited by 775 · see citing works
Hunter, T. R. (1991) · Cell · doi:10.1016/0092-8674(91)90637-e · Cited by 757 · see citing works
Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704 · see citing works
Mapping of the p53 and mdm-2 Interaction Domains
Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · see citing works
Lee, W., Shew, J., Hong, F., Sery, T. W., Donoso, L. A., Young, L.-J., Bookstein, R., & Lee, E. Y.-H. P. (1987) · Nature · doi:10.1038/329642a0 · Cited by 628 · see citing works
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586 · see citing works
p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach, F. S., Tokino, T., Meltzer, P. S., Burrell, M., Oliner, J., Smith, S., HILL, D. E., Sidransky, D., Kinzler, K. W., & Vogelstein, B. (1993) · PubMed · Cited by 533 · see citing works
Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.Preprint
Zhu, L., van den Heuvel, S., Helin, K., Fattaey, A., Ewen, M. E., Livingston, D. M., Dyson, N. J., & Harlow, E. E. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1111 · Cited by 516 · see citing works
(1994) · PubMed · Cited by 509 · see citing works
Levine, A. J. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.003203 · Cited by 506 · see citing works
Rearrangement of the p53 gene in human osteogenic sarcomas.
Masuda, H., Miller, C., Koeffler, H. P., Battifora, H. A., & Cline, M. J. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7716 · Cited by 473 · see citing works
(1993) · PubMed · Cited by 469 · see citing works
Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein
Martin, K., Trouche, D., Hagemeier, C., Sørensen, T. S., Thangue, N. B. L., & Kouzarides, T. (1995) · Nature · doi:10.1038/375691a0 · Cited by 454 · see citing works
Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone, D. P., D'Amico, D., Bodner, S. M., Oie, H. K., Linnoila, R. I., Mulshine, J. L., & Minna, J. D. (1992) · Lung Cancer · doi:10.1016/0169-5002(92)90040-q · Cited by 441 · see citing works
Sugden, B., Marsh, K., & Yates, J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.2.410 · Cited by 438 · see citing works
Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., & Levine, A. J. (1990) · PubMed · Cited by 408 · see citing works
mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein
Chen, J., Wu, X., Lin, J., & Levine, A. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.5.2445 · Cited by 350 · see citing works
MDM2 gene amplification in metastatic osteosarcoma.
Ladanyi, M., Cha, C. H., Lewis, R., Jhanwar, S. C., Huvos, A. G., & Healey, J. H. (1993) · PubMed · Cited by 342 · see citing works
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.
Khatib, Z. A., Matsushime, H., Valentine, M. B., Shapiro, D. N., Sherr, C. J., & Look, A. T. (1993) · PubMed · Cited by 339 · see citing works
Juven‐Gershon, T., Barak, Y., Zauberman, A., George, D. L., & Oren, M. (1993) · PubMed · Cited by 332 · see citing works
Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328 · see citing works
The Ribosomal L5 Protein Is Associated with mdm-2 and mdm-2-p53 Complexes
Maréchal, V., Elenbaas, B., Piette, J., Nicolas, J. C., & Levine, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414 · Cited by 318 · see citing works
Mittnacht, S., & Weinberg, R. A. (1991) · Cell · doi:10.1016/0092-8674(91)90456-9 · Cited by 311 · see citing works
The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301 · Cited by 311 · see citing works
Reifenberger, G., REIFENBERGER, J., Ichimura, K., Meltzer, P. S., & Collins, V. P. (1994) · PubMed · Cited by 279 · see citing works
Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.
Chen, C. Y., Oliner, J., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271 · see citing works
Band, V., & Sager, R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.4.1249 · Cited by 269 · see citing works
Sigalas, I., Calvert, A. H., Anderson, J. J., Neal, D. E., & Lunec, J. (1996) · Nature Medicine · doi:10.1038/nm0896-912 · Cited by 268 · see citing works
The mdm-2 gene is induced in response to UV light in a p53-dependent manner.
Perry, M. E., Piette, J., Zawadzki, J., Harvey, D., & Levine, A. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11623 · Cited by 247 · see citing works
Mapping of the p53 and mdm-2 Interaction Domains
Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107-4114.1993 · Cited by 247 · see citing works
Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., & Finlay, C. A. (1997) · Genes & Development · doi:10.1101/gad.11.6.714 · Cited by 235 · see citing works
Cell type‐specific inhibition of p53‐mediated apoptosis by mdm2.
Haupt, Y., Barak, Y., & Oren, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00504.x · Cited by 228 · see citing works
p53 Functions as a Cell Cycle Control Protein in Osteosarcomas
Diller, L., Kassel, J., Nelson, C. E., et al. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.11.5772-5781.1990 · Cited by 228 · see citing works
Picksley, S. M., & Lane, D. P. (1993) · BioEssays · doi:10.1002/bies.950151008 · Cited by 207 · see citing works
Lane, D. P. (1994) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a072911 · Cited by 195 · see citing works
Sugden, B., Marsh, K., & Yates, J. (1985) · Molecular and Cellular Biology · doi:10.1128/mcb.5.2.410-413.1985 · Cited by 189 · see citing works
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.
Olson, D. C., Maréchal, V., Momand, J. A., Chen, J., Romocki, C., & Levine, A. J. (1993) · PubMed · Cited by 188 · see citing works
MDM2 Gene Amplification and Transcript Levels in Human Sarcomas: Relationship to TP53 Gene Status
Flørenes, V. A., Mælandsmo, G. M., Forus, A., Andreassen, Å. K., Myklebost, O., & Fodstad, Ø. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.17.1297 · Cited by 188 · see citing works
Tumor progression in four mammary epithelial cell lines derived from the same patient.
Band, V., Zajchowski, D. A., Swisshelm, K. L., Trask, D. K., Kulesa, V., Cohen, C., Connolly, J. L., & Sager, R. (1990) · PubMed · Cited by 176 · see citing works
Inhibition of viral and cellular promoters by human wild-type p53
Subler, M. A., Martin, D. W., & Deb, S. (1992) · Journal of Virology · doi:10.1128/jvi.66.8.4757-4762.1992 · Cited by 171 · see citing works
C-terminal truncation of the retinoblastoma gene product leads to functional inactivation.
Shew, J., Lin, B. T., Chen, P., Tseng, B., Yang‐Feng, T. L., & Lee, W. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.1.6 · Cited by 164 · see citing works
Nuclear location signal-mediated protein transport
Roberts, B. (1989) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(89)90016-x · Cited by 140 · see citing works
Physical and Functional Interaction between Wild-Type p53 and mdm2 Proteins
Haines, D. S., Landers, J. E., Engle, L. J., & George, D. L. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1171 · Cited by 136 · see citing works
The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma.
Sheikh, M. S., Shao, Z. M., Hussain, A., & Fontana, J. A. (1993) · PubMed · Cited by 127 · see citing works
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120 · see citing works
Self-citationPollice, A. A., McCoy, J. P., Shackney, S. E., Smith, C. A., Agarwal, J., Burnolt, D. R., Janocko, L. E., Hornicek, F. J., Singh, S. G., & Hartsock, R. J. (1992) · Cytometry · doi:10.1002/cyto.990130414 · Cited by 111 · see citing works
The Ribosomal L5 Protein Is Associated with mdm-2 and mdm-2-p53 Complexes
Maréchal, V., Elenbaas, B., Piette, J. G., et al. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414-7420.1994 · Cited by 107 · see citing works
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors.
Linardopoulos, S., Street, A. J., Quelle, D. E., Parry, D., Peters, G. G., Sherr, C. J., & Balmain, A. (1995) · PubMed · Cited by 105 · see citing works
The mdm-2 Oncogene Can Overcome Wild-Type p53 Suppression of Transformed Cell Growth
Finlay, C. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.1.301-306.1993 · Cited by 83 · see citing works
Gudas, J. M., Nguyen, H., Klein, R. C., Katayose, D., Seth, P. K., & Cowan, K. H. (1995) · PubMed · Cited by 74 · see citing works
DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells.
Price, B. D., & Park, S. J. (1994) · PubMed · Cited by 73 · see citing works
Cloning and characterization of murine p16INK4a and p15INK4b genes.
Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., & Serrano, M. (1995) · PubMed · Cited by 69 · see citing works
MDM2 gene amplification in human breast cancer
Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P., & Peyrat, J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90128-7 · Cited by 67 · see citing works
Amplification of a gene encoding a p53-associated protein in human sarcomas
(1992) · Trends in Genetics · doi:10.1016/0168-9525(92)90271-5 · Cited by 64 · see citing works
Brown, D. R., Deb, S., Muñoz, R. M., Subler, M. A., & Deb, S. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6849 · Cited by 58 · see citing works
Self-citationCell Cycle — Materials and Methods
Pagano, M. (1996) · Springer eBooks · doi:10.1007/978-3-642-57783-3 · Cited by 52 · see citing works
Leng, R. P., Brown, D. R., Shivakumar, C., Deb, S., & Deb, S. (1995) · PubMed · Cited by 48 · see citing works
Self-citationLevine, A. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.623 · Cited by 47 · see citing works
Upregulation of mdm-2 expression in Meth A tumor cells tolerating wild-type p53.
Otto, A., & Deppert, W. (1993) · PubMed · Cited by 41 · see citing works
Physical and Functional Interaction between Wild-Type p53 and mdm2 Proteins
Haines, D. S., Landers, J. E., Engle, L. J., et al. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1171-1178.1994 · Cited by 40 · see citing works
Analysis of Flow Cytometry Data
Sharrow, S. O. (1991) · Current Protocols in Immunology · doi:10.1002/0471142735.im0502s00 · Cited by 30 · see citing works
Induction of p53-, MDM2-, and WAF1/CIP1-like Molecules in Insect Cells by DNA-Damaging Agents
Bae, I., Smith, M. L., & Fornace, A. J. (1995) · Experimental Cell Research · doi:10.1006/excr.1995.1120 · Cited by 25 · see citing works
MDM2 overexpression in benign and malignant lesions of the human breast
Baunoch, D., Watkins, L. F., Tewari, A., Reece, M. T., Adams, L. M., Stack, R., Brown, A., Jones, L. A., Christian, D., Latif, N. A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.8.5.895 · Cited by 22 · see citing works
Brown, D. R., Deb, S., Muñoz, R. M., et al. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.11.6849-6857.1993 · Cited by 22 · see citing works
Self-citationHUMAN ONCOPROTEIN MDM2 INTERACTS WITH THE TATA-BINDING PROTEIN IN-VITRO AND IN-VIVO
Leng, R. P., Brown, D. R., Deb, S. P., & Deb, S. P. (1995) · International Journal of Oncology · doi:10.3892/ijo.6.1.251 · Cited by 19 · see citing works
Self-citationSelective compartmentalization of different mdm2 proteins within the nucleus.
Maxwell, S. A. (1995) · PubMed · Cited by 13 · see citing works
TRANSCRIPTIONAL ANTAGONISM BETWEEN P53 AND SV40 T-ANTIGEN
Deb, S., Brown, D. R., LEGA, H., & Deb, S. P. (1995) · International Journal of Oncology · doi:10.3892/ijo.6.1.243 · Cited by 3 · see citing works
Self-citationWang (1997) · doi:10.1002/(sici)1096-9896(199705)182:1
Flagged first, then by citations
Cited by
Sorted by citations
Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 407 · see citing works
The Mdm2–p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor
Manfredi, J. J. (2010) · Genes & Development · doi:10.1101/gad.1941710 · Cited by 344 · see citing works
Alternative and aberrant splicing of MDM2 mRNA in human cancer
Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196 · see citing works
Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193 · see citing works
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 149 · see citing works
(2003) · PubMed · Cited by 147 · see citing works
Lind, H., Zienolddiny, S., Ekstrøm, P. O., Skaug, V., & Haugen, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21872 · Cited by 144 · see citing works
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2
Evans, S. C., Viswanathan, M., Grier, J. D., Narayana, M., El‐Naggar, A. K., & Lozano, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204533 · Cited by 138 · see citing works
The roles and regulation of MDM2 and MDMX: it is not just about p53Preprint
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 132 · see citing works
Gazzéri, S., Della-Valle, V., Chaussade, L., Brambilla, C., Larsen, C., & Brambilla, E. M. (1998) · PubMed · Cited by 126 · see citing works
p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop
Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 126 · see citing works
MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas
Balik, V., Srovnal, J., Sulla, I. J., Kalita, O., Foltánová, T., Vaverka, M., Hrabálek, L., & Hajdúch, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-1038-6 · Cited by 125 · see citing works
Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells
Schwarze, S. R., DePrimo, S. E., Grabert, L. M., Fu, V. X., Brooks, J. D., & Jarrard, D. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200373200 · Cited by 119 · see citing works
Wienken, M., Dickmanns, A., Nemajerová, A., Kramer, D., Najafova, Z., Weiss, M., Karpiuk, O., Kassem, M. S., Zhang, Y., Lozano, G., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.12.008 · Cited by 109 · see citing works
DDB2 decides cell fate following DNA damage
Stoyanova, T., Roy, N., Kopanja, D., Bagchi, S., & Raychaudhuri, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812254106 · Cited by 108 · see citing works
Analysis of the degradation function of Mdm2.
Kubbutat, M. H. G., Ludwig, R., Levine, A. J., & Vousden, K. H. (1999) · PubMed · Cited by 102 · see citing works
Daujat, S., NEEL, H., & PIETTE, J. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02369-1 · Cited by 97 · see citing works
Cell cycle regulatory functions of the human oncoprotein MDM2.
Deb, S. P. (2003) · PubMed · Cited by 96 · see citing works
Nuclear exclusion of p53 in a subset of tumors requires MDM2 function
Lu, W., Pochampally, R. R., Chen, L., Chomnawang, M. T., Wang, Y., & Chen, J. (2000) · Oncogene · doi:10.1038/sj.onc.1203262 · Cited by 90 · see citing works
Dissociation of the recombination control and the sequence-specific transactivation function of P53
Dudenhöffer, C., Kurth, M., Janus, F., Deppert, W., & Wiesmüller, L. (1999) · Oncogene · doi:10.1038/sj.onc.1202964 · Cited by 89 · see citing works
The RING domain of Mdm2 can inhibit cell proliferation.
Dang, J., Kuo, M.-L., Eischen, C. M., Stepanova, L., Sherr, C. J., & Roussel, M. F. (2002) · PubMed · Cited by 86 · see citing works
p53 Activity Results in DNA Replication Fork Processivity
Klusmann, I., Rodewald, S., Müller, L., Friedrich, M., Wienken, M., Li, Y., Schulz‐Heddergott, R., & Dobbelstein, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.036 · Cited by 82 · see citing works
Tumor promotion by Mdm2 splice variants unable to bind p53.
Fridman, J. S., Hernando, E., Hemann, M. T., de Stanchina, E., Cordon‐Cardo, C., & Lowe, S. W. (2003) · PubMed · Cited by 82 · see citing works
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79 · see citing works
Dysregulated glycolysis as an oncogenic event
Mikawa, T., LLeonart, M. E., Takaori‐Kondo, A., Inagaki, N., Yokode, M., & Kondoh, H. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1840-3 · Cited by 80 · see citing works
Scission of the p53-MDM2 Loop by Ribosomal Proteins
Zhou, X. Y., Liao, J.-M., Liao, W.-J., & Lu, H. (2012) · Genes & Cancer · doi:10.1177/1947601912455200 · Cited by 78 · see citing works
Wang, Y.-C., Lin, R.-K., Tan, Y. C., Chen, J.-T., Chen, C., & Wang, Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.139 · Cited by 77 · see citing works
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 72 · see citing works
DDB2 (damaged-DNA binding protein 2) in nucleotide excision repair and DNA damage response
Stoyanova, T., Roy, N., Kopanja, D., Raychaudhuri, P., & Bagchi, S. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10109 · Cited by 70 · see citing works
Seavey, S. E., Holubar, M. K., Saucedo, L. J., & Perry, M. E. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7590-7598.1999 · Cited by 69 · see citing works
Tsai, S.-C., Pasumarthi, K. B. S., Pajak, L., Franklin, M. T., Patton, B. L., Wang, H., Henzel, W. J., Stults, J. T., & Field, L. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3239 · Cited by 70 · see citing works
Regulation of p53 and MDM2 Activity by MTBP
Brady, M., Vlatković, N., & Boyd, M. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.545-553.2005 · Cited by 69 · see citing works
Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase
Giono, L. E., Resnick‐Silverman, L., Carvajal, L. A., Clair, S. S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.254 · Cited by 67 · see citing works
Wei, W., Jobling, W. A., Chen, W., Hahn, W. C., & Sedivy, J. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2859-2870.2003 · Cited by 68 · see citing works
Lindström, M. S., Deisenroth, C., & Zhang, Y. (2007) · Cell Cycle · doi:10.4161/cc.6.4.3861 · Cited by 65 · see citing works
Total Synthesis of Chlorofusin, Its Seven Chromophore Diastereomers, and Key Partial Structures
Clark, R. C., Lee, S. Y., & Boger, D. L. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8012819 · Cited by 65 · see citing works
The Many Faces of MDM2 Binding Partners
Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 64 · see citing works
MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis
Li, G. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl047 · Cited by 63 · see citing works
Giono, L. E., & Manfredi, J. J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01967-06 · Cited by 62 · see citing works
Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication
Klusmann, I., Wohlberedt, K., Magerhans, A., Teloni, F., Korbel, J. O., Altmeyer, M., & Dobbelstein, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809592115 · Cited by 62 · see citing works
Giglio, S., Mancini, F., Gentiletti, F., Sparaco, G., Felicioni, L., Barassi, F., Martella, C., Prodosmo, A., Iacovelli, S., Buttitta, F., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0450 · Cited by 58 · see citing works
Mdm2: A Regulator of Cell Growth and Death
Alarcon-Vargas, D., Takahashi, S., & Ronai, Z. A. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)01001-7 · Cited by 57 · see citing works
Mdm2 and MdmX as Regulators of Gene Expression
Biderman, L., Manley, J. L., & Prives, C. L. (2012) · Genes & Cancer · doi:10.1177/1947601912455331 · Cited by 55 · see citing works
MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination
Maguire, M., Nield, P. C., Devling, T., Jenkins, R. E., Park, B. K., Polański, R., Vlatković, N., & Boyd, M. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5271 · Cited by 53 · see citing works
Bartel, F., Harris, L. C., Würl, P., & Taubert, H. W. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.29.2.1 · Cited by 52 · see citing works
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation
Hallenborg, P., Feddersen, S., Francoz, S., Murano, I., Sundekilde, U. K., Petersen, R. K., Akimov, V., Olson, M. V., Lozano, G., Cinti, S., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.15 · Cited by 52 · see citing works
Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
van Leeuwen, I. M. M., Higgins, M., Campbell, J., McCarthy, A. R., Sachweh, M. C. C., Navarro, A. M., & Laı́n, S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0904 · Cited by 45 · see citing works
Role of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45 · see citing works
Analysis of the molecular species generated by mdm2 gene amplification in liposarcomas
Tamborini, E., Torre, G. D., Lavarino, C. E., Azzarelli, A., Carpinelli, P., Pierotti, M. A., & Pilotti, S. (2001) · International Journal of Cancer · doi:10.1002/ijc.1271 · Cited by 46 · see citing works
Mdm2 and Tumorigenesis: Evolving Theories and Unsolved Mysteries
Senturk, E., & Manfredi, J. J. (2012) · Genes & Cancer · doi:10.1177/1947601912457368 · Cited by 46 · see citing works
Function and dysfunction of the human oncoprotein MDM2
Deb, S. P. (2002) · Frontiers in bioscience · doi:10.2741/a723 · Cited by 45 · see citing works
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication
Singh, S., Vaughan, C. A., Frum, R. A., Grossman, S. R., Deb, S., & Deb, S. P. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87724 · Cited by 44 · see citing works
Yu, Z.-C., Huang, Y., & Shieh, S.-Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1173 · Cited by 44 · see citing works
Senescence-inducing stress promotes proteolysis of phosphoglycerate mutase via ubiquitin ligase Mdm2
Mikawa, T., Maruyama, T., Okamoto, K., Nakagama, H., LLeonart, M. E., Tsusaka, T., Hori, K., Murakami, I., Izumi, T., Takaori‐Kondo, A., et al. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201306149 · Cited by 43 · see citing works
MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change
Xu, H., Zhang, Z., Li, M., & Zhang, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059568 · Cited by 41 · see citing works
Clark, R. C., Lee, S. Y., Searcey, M., & Boger, D. L. (2009) · Natural Product Reports · doi:10.1039/b821676b · Cited by 41 · see citing works
Solution structure of the C4 zinc finger domain of HDM2
Yu, G. W., Allen, M. D., Andreeva, A. E., Fersht, A. R., & Bycroft, M. (2005) · Protein Science · doi:10.1110/ps.051927306 · Cited by 40 · see citing works
Gorgoulis, V. G., Zacharatos, P., Kotsinas, A., Mariatos, G., Liloglou, T., Vogiatzi, T., Foukas, P., Rassidakis, G. Z., Garinis, G. A., Ioannides, T., et al. (2000) · Molecular Medicine · doi:10.1007/bf03402115 · Cited by 38 · see citing works
Identification of a CK2 phosphorylation site in mdm2.
Götz, C., Kartarius, S., Scholtes, P., Nastainczyk, W., & Montenarh, M. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00882.x · Cited by 39 · see citing works
MDM2 309 polymorphism is associated with missed abortion
Fang, Y., Kong, B., Yang, Q., Ma, D., & Qu, X. (2009) · Human Reproduction · doi:10.1093/humrep/dep044 · Cited by 39 · see citing works
Dobbelstein, M., & Levine, A. J. (2020) · Cancer Science · doi:10.1111/cas.14433 · Cited by 38 · see citing works
Kurokawa, K., Tanaka, T., & Kato, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202628 · Cited by 37 · see citing works
Frum, R. A., Singh, S. K., Vaughan, C. A., Mukhopadhyay, N. D., Grossman, S. R., Windle, B. E., Deb, S., & Deb, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt944 · Cited by 36 · see citing works
The contribution of the RING finger domain of MDM2 to cell cycle progression
Argentini, M., Barboule, N., & Wasylyk, B. (2000) · Oncogene · doi:10.1038/sj.onc.1203737 · Cited by 35 · see citing works
Wang, Y., Zheng, Z., Zhang, J., Wang, Y., Kong, R., Liu, J., Zhang, Y., Deng, H., Du, X., & Ke, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655597 · Cited by 33 · see citing works
Inhibitors of MDM2 and MDMX: A Structural Perspective
Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 32 · see citing works
Neel, H., Daujat, S., Piette, J., Thisse, C., & Thisse, B. (2000) · Differentiation · doi:10.1046/j.1432-0436.2000.660201.x · Cited by 31 · see citing works
mdm2 mRNA Level is a Prognostic Factor in Soft Tissue Sarcoma
Taubert, H. W., Koehler, T., Meye, A., Bartel, F., Lautenschläger, C., Borchert, S., Bache, M., Schmidt, H., & Würl, P. (2000) · Molecular Medicine · doi:10.1007/bf03401934 · Cited by 30 · see citing works
Akkız, H., Sümbül, A. T., Bayram, S., Bekar, A., & Akgöllü, E. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.04.008 · Cited by 28 · see citing works
Overexpression of p21 and MDM2 characterizes serous borderline ovarian tumors
Palazzo, J., Monzon, F. A., BURKE, M., Hyslop, T., Dunton, C. J., Barusevicius, A., Capuzzi, D. M., & Kovatich, A. J. (2000) · Human Pathology · doi:10.1053/hupa.2000.7641 · Cited by 28 · see citing works
Dias, C. S., Liu, Y., Yau, A., Westrick, L., & Evans, S. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3013 · Cited by 27 · see citing works
Gangwar, R., & Mittal, R. D. (2010) · DNA and Cell Biology · doi:10.1089/dna.2009.0982 · Cited by 26 · see citing works
Polański, R., Maguire, M., Nield, P. C., Jenkins, R. E., Park, B. K., Krawczyńska, K., Devling, T., Ray‐Sinha, A., Rubbi, C. P., Vlatković, N., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr070 · Cited by 26 · see citing works
Overexpression of mouse Mdm2 induces developmental phenotypes in Drosophila
Folberg-Blum, A., Sapir, A., Shilo, B., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205305 · Cited by 26 · see citing works
MDM2 Controls the Timely Expression of Cyclin A to Regulate the Cell Cycle
Frum, R. A., Ramamoorthy, M., Mohanraj, L., Deb, S., & Deb, S. P. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0334 · Cited by 25 · see citing works
Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis
Gannon, H., & Jones, S. N. (2012) · Genes & Cancer · doi:10.1177/1947601912455324 · Cited by 25 · see citing works
The post-genomic era of interactive proteomics: Facts and perspectives
Auerbach, D., Thaminy, S., Hottiger, M. O., & Štagljar, I. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200206)2:6 · Cited by 134 · see citing works
A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle
Li, H., Dong, L., Jin, M.-J., Li, Q.-Y., Wang, X. Q., Jia, M., Song, J., Zhang, S., & Yuan, S. (2023) · Molecules · doi:10.3390/molecules28031141 · Cited by 25 · see citing works
Zhou, R., Frum, R. A., Deb, S., & Deb, S. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3755 · Cited by 24 · see citing works
Impact ofMDM2single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma
Nakashima, M., Kondo, S., Shimizu, Y., Wakisaka, N., Murono, S., Furukawa, M., & Yoshizaki, T. (2008) · Acta Oto-Laryngologica · doi:10.1080/00016480701724904 · Cited by 24 · see citing works
MDM2 Splice Variants and Their Therapeutic Implications
Harris, L. C. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332654 · Cited by 24 · see citing works
HDM2-Binding Partners: Interaction with Translation Elongation Factor EF1α
Frum, R. A., Busby, S. A., Ramamoorthy, M., Deb, S., Shabanowitz, J., Hunt, D. F., & Deb, S. P. (2007) · Journal of Proteome Research · doi:10.1021/pr060584p · Cited by 23 · see citing works
MDM2 promotes cell motility and invasiveness through a RING‐finger independent mechanism
Polański, R., Warburton, H. E., Ray‐Sinha, A., Devling, T., Pakula, H., Rubbi, C. P., Vlatković, N., & Boyd, M. T. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.10.049 · Cited by 22 · see citing works
Alternative splicing ofMDM2 mRNA in lung carcinomas and lung cell lines
Weng, M.-W., Lai, J.-C., Hsu, C.-P., Yu, K.-Y., Chen, C., Lin, T.-S., Lai, W., Lee, H., & Ko, J. (2005) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20118 · Cited by 22 · see citing works
Sánchez‐Aguilera, A., García, J. F., Sánchez‐Beato, M., & Piris, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1209282 · Cited by 21 · see citing works
The MDM2 Oncoprotein Promotes Apoptosis in p53-Deficient Human Medullary Thyroid Carcinoma Cells
Dilla, T., Velasco, J. A., Medina, D. L., Jf, G.-P., & Santisteban, P. (2000) · Endocrinology · doi:10.1210/endo.141.1.7265 · Cited by 23 · see citing works
Serous tumors of low malignant potential of the ovary-molecular pathology: part 2
Hauptmann, S., & Dietel, M. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280100435 · Cited by 21 · see citing works
Fussenegger, M., & Bailey, J. E. (2007) · Springer eBooks · doi:10.1007/978-0-585-37971-5_7 · Cited by 21 · see citing works
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20 · see citing works
Hinokiflavone Inhibits MDM2 Activity by Targeting the MDM2-MDMX RING Domain
Ilic, V. K., Egorova, O., Tsang, E., Gatto, M., Wen, Y., Zhao, Y., & Sheng, Y. (2022) · Biomolecules · doi:10.3390/biom12050643 · Cited by 20 · see citing works
MDM2 SNP309 contributes to non‐small cell lung cancer survival in Chinese
Dong, J., Ren, B., Hu, Z., Chen, J., Hu, L., Dai, J., Jin, G., Xu, L., & Shen, H. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20727 · Cited by 20 · see citing works
Schuster, K., Fan, L., & Harris, L. C. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0146 · Cited by 20 · see citing works
Fang, Y., Kong, B., Yang, Q., Ma, D., & Qu, X. (2011) · Human Reproduction · doi:10.1093/humrep/der017 · Cited by 20 · see citing works
Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women
Zając, A. E., Stachowiak, G., Pertyński, T., Romanowicz, H., Wilczyński, J. R., & Smolarz, B. (2013) · Polish Journal of Pathology · doi:10.5114/pjp.2012.32776 · Cited by 19 · see citing works
Thromboxane A2 modulates cisplatin-induced apoptosis through a Siva1-dependent mechanism
Iorio‐Morin, C., Germain, P., Roy, S. J., Génier, S., Labrecque, P., & Parent, J. L. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.11 · Cited by 19 · see citing works
MDM2 Overexpression, Activation of Signaling Networks, and Cell Proliferation
Deb, S. P., Singh, S., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_12 · Cited by 17 · see citing works
MicroRNA-26a targets the mdm2/p53 loop directly in response to liver regeneration
Zhou, J., Li, Z., Huang, Y., Ju, W., Wang, D., Zhu, X., & He, X. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4282 · Cited by 16 · see citing works
Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16 · see citing works
Shi, W., Meng, Z., Chen, Z., Hua, Y., Gao, H., Wang, P., Lin, J., Zhou, Z., Luo, J., & Liu, L. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1208-4 · Cited by 16 · see citing works
Abdel-Hamid, E. S., & Elmalahy, M. H. (2010) · Diagnostic Pathology · doi:10.1186/1746-1596-5-72 · Cited by 16 · see citing works
- Authors
- Brown, D. R., Thomas, C. A., & Palit Deb, S.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- ORCID
- Brown, Doris R.
- Venue
- The EMBO Journal
- Published
- 1998-05-01
- Volume
- 17
- Issue
- 9
- Pages
- 2513-2525
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC1170593
- OpenAlex
- W2014749419
- Cited by
- 148
- References
- 78
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 14
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The EMBO Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R01CA070712, CA70712)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, oncoprotein, cell cycle arrest, G0/G1 arrest, carcinogenesis, deletion mutants, NIH3T3 cells, cancer cell lines, oncogene overexpression, growth inhibition
- MeSH terms
- Animals, Cell Cycle, Cell Division, Cell Line, Cell Transformation, Neoplastic, Flow Cytometry, Gene Amplification, Humans, Neoplasm Proteins, Nuclear Proteins, Proto-Oncogene Proteins, Recombinant Proteins, Transfection, Resting Phase, Cell Cycle, G1 Phase, S Phase, Mutagenesis, Site-Directed, 3T3 Cells, Sequence Deletion, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
